(Q43032141)

English

Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate

scientific article published in May 2001

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Cytokine network in nonresponding chronic hepatitis C patients with genotype 1: role of triple therapy with interferon alpha, ribavirin, and ursodeoxycholate (English)

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

1 reference

based on heuristic

inferred from title

chronic hepatitis C

1 reference

based on heuristic

inferred from title

author name string

Neuman MG

1

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Blendis LM

2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Shear NH

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Malkiewicz IM

4

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Ibrahim A

5

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Katz GG

6

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sapir D

7

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Halpern Z

8

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Brill S

9

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Peretz H

10

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Magazinik S

11

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Konikoff FM

12

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

publication date

1 May 2001

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Clinical Biochemistry

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

34

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

183-188

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Pathogenesis, diagnosis and management of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Increases in intrahepatic CD68 positive cells, MAC387 positive cells, and proinflammatory cytokines (particularly interleukin 18) in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Interferon-alpha plus ribavirin in chronic hepatitis C resistant to previous interferon-alpha course: results of a randomized multicenter trial.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Long-term treatment of chronic hepatitis C with ursodeoxycholic acid: influence of HCV genotypes and severity of liver disease

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Retreatment with interferon-alpha and ribavirin in primary interferon-alpha non-responders with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Interferon-ribavirin combination therapy for chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Randomised, double-blind, placebo-controlled trial of interferon alpha-2b with and without ribavirin for chronic hepatitis C. The Swedish Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Ribavirin enhances the efficacy but not the adverse effects of interferon in chronic hepatitis C. Meta-analysis of individual patient data from European centers.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

A phase I/II study of recombinant human interleukin-12 in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Predictors of sustained response to alpha interferon therapy in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Quantification of serum hepatitis C virus RNA with daily or standard interferon doses plus ribavirin in nonresponder patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Host genetic factors influence disease progression in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

New treatment strategies in non-responder patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Is an "a la carte" combination interferon alfa-2b plus ribavirin regimen possible for the first line treatment in patients with chronic hepatitis C? The ALGOVIRC Project Group

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Interferon-ribavirin for chronic hepatitis C with and without cirrhosis: analysis of individual patient data of six controlled trials. Eurohep Study Group for Viral Hepatitis.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Interleukin-10 promoter polymorphism predicts initial response of chronic hepatitis C to interferon alfa

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Treating histologically mild chronic hepatitis C: monotherapy, combination therapy, or tincture of time?

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Early prediction of response in interferon monotherapy and in interferon-ribavirin combination therapy for chronic hepatitis C: HCV RNA at 4 weeks versus ALT.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Interferon alfa-2b alone or in combination with ribavirin for the treatment of relapse of chronic hepatitis C. International Hepatitis Interventional Therapy Group

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Factors predictive of a beneficial response to therapy of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Chronic hepatitis C virus infections: predictive value of genotype and level of viraemia on disease progression and response to interferon alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Early addition of ribavirin to interferon in chronic hepatitis C not responsive to interferon monotherapy

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Treatment of chronic hepatitis C with interferon with or without ursodeoxycholic acid: a randomized prospective trial

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Gallstone dissolution with ursodeoxycholic acid in patients with chronic active hepatitis and two years follow-up. A pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Cytokines and the liver

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Decreased frequency of HCV core-specific peripheral blood mononuclear cells with type 1 cytokine secretion in chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Pathogenesis, natural history, treatment, and prevention of hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Role of cytokines in ethanol-induced cytotoxicity in vitro in Hep G2 cells

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Increased monocyte nuclear factor-kappaB activation and tumor necrosis factor production in alcoholic hepatitis

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Impact of interferon alfa-2b and ribavirin on progression of liver fibrosis in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Fas-mediated apoptosis of peripheral blood mononuclear cells in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Hepatic Fas antigen expression before and after interferon therapy in patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Serum concentrations of sIL-2R, IL-6, TGF-beta1, neopterin, and zinc in chronic hepatitis C patients treated with interferon-alpha

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Inflammatory markers in chronic hepatitis C

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Role of transforming growth factor beta type II receptor in hepatic fibrosis: studies of human chronic hepatitis C and experimental fibrosis in rats

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Histological features predictive of liver fibrosis in chronic hepatitis C infection

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon nonresponders

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

A pilot study of daily subcutaneous interleukin-10 in patients with chronic hepatitis C infection.

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

Combination therapy for chronic hepatitis C: interferon and ribavirin

1 reference

https://api.crossref.org/works/10.1016%2FS0009-9120%2801%2900213-2

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S0009-9120(01)00213-2

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

12 November 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q43032141&oldid=1977655838"